Our study aimed to assess the expression of CDX2 in gastric adenocarcinoma by immunohistochemistry in addition to investigating the relationship between CDX2 expression and some clinicopathological parameters, such as the age and gender of patients, as well as tumor type, tumor grade, lymphovascular invasion, lymph node status, and tumor stage. Here, CDX2 is linked to gastric adenocarcinoma.